These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31372346)

  • 1. Renoprotective effects of stevia (
    Rizwan F; Yesmine S; Banu SG; Chowdhury IA; Hasan R; Chatterjee TK
    Toxicol Rep; 2019; 6():683-691. PubMed ID: 31372346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dataset concerning effects of stevia (
    Rizwan F; Yesmine S; Chowdhury IA; Banu SG; Chatterjee TK
    Data Brief; 2020 Aug; 31():105965. PubMed ID: 32671162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary analysis of the effect of Stevia (
    Rizwan F; Rashid HU; Yesmine S; Monjur F; Chatterjee TK
    Contemp Clin Trials Commun; 2018 Dec; 12():17-25. PubMed ID: 30211340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose angiotensin AT
    Esmaeeli A; Ebrahimi F; Tanha K; Assadi M; Seyedabadi M
    Pharmacol Rep; 2020 Dec; 72(6):1676-1684. PubMed ID: 33090352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
    Aritomi S; Koganei H; Wagatsuma H; Mitsui A; Ogawa T; Nitta K; Konda T
    Heart Vessels; 2010 Nov; 25(6):549-55. PubMed ID: 20922532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and bioaccumulation of manganese and chromium in different organs of common carp (
    Ali Z; Yousafzai AM; Sher N; Muhammad I; Nayab GE; Aqeel SAM; Shah ST; Aschner M; Khan I; Khan H
    Toxicol Rep; 2021; 8():343-348. PubMed ID: 33659190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
    Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
    J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N; Cilan H; Sipahioglu M; Unal A; Kocyigit I; Kavuncuoglu F; Arikan T; Akpek M; Elcik D; Sahin O; Gulme E; Pala C; Tokgoz B; Utas C; Oguzhan A; Oymak O
    Ren Fail; 2013; 35(4):434-9. PubMed ID: 23413781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
    Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematological and toxicological effects of aqueous leaf extract of Stevia rebaudiana Bertoni in normal rat modals.
    Ahmad U; Ahmad RS; Shahbaz M; Imran A; Haseeb M; Siddique F; Yasmin Z; Ashraf I; Masroor A; Basit A
    Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2249-2255. PubMed ID: 33832898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockout of the aryl hydrocarbon receptor results in distinct hepatic and renal phenotypes in rats and mice.
    Harrill JA; Hukkanen RR; Lawson M; Martin G; Gilger B; Soldatow V; Lecluyse EL; Budinsky RA; Rowlands JC; Thomas RS
    Toxicol Appl Pharmacol; 2013 Oct; 272(2):503-18. PubMed ID: 23859880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences.
    Haghighi M; Nematbakhsh M; Talebi A; Nasri H; Ashrafi F; Roshanaei K; Eshraghi-Jazi F; Pezeshki Z; Safari T
    Ren Fail; 2012; 34(8):1046-51. PubMed ID: 22780575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK; El-Maraghy SA; Senousy MA
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
    Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.